|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Bioprocessing company that develops, produces and commercializes innovative biologic drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.
Market cap: 2,4B USD P/E: 107,11 Consensus recommendation: Strong buy Revenue: 141,24 million (2017, +35,1 %)
Company is assessed positively by analysts and has a solid “buy” recommendation. They operate in a growing market segment in which they have good potential to create value for investors.